Clinical Trials
4 trialsNCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04836832 2022-06-07
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04660045 2022-04-05
Early Intervention With Acalabrutinib in Patients With High Risk CLL
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT04961801 2022-03-08
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Withdrawn